This is the text extract for Proposal for lansoprazole (Solox). Closed, browse documents here.

4 September 2009

Proposal for lansoprazole (Solox)

PHARMAC is seeking feedback on a proposal for lansoprazole (Solox) through a provisional agreement with Douglas Pharmaceuticals. Lansoprazole is a proton-pump inhibitor used for various conditions including reflux oesophagitis, duodenal and gastric ulcers. If implemented, the proposal would result in a subsidy and price reduction for Solox in return for subsidy and delisting protection.

Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm on Friday 18 September 2009 to: Mike Bignall Therapeutic Group Manager PHARMAC Email: mike.bignall@pharmac.govt.nz Fax: 04 460 4995 Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal • The listing of Solox would be amended in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 November 2009 as follows:

Form and Strength Cap 15 mg Cap 30 mg Current price and subsidy $4.30 $8.59 Proposed price and subsidy $3.50 $4.65

Chemical

Brand

Pack size 28 28

Lansoprazole

Solox

Prices are ex-manufacturer, excluding GST

•

Solox would have subsidy and delisting protection until 31 October 2012.

A264370 Page 1 of 1